Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging
18 februari, 09:20
Lumito AB (publ) (“Lumito” or the “Company”) and Atlas Antibodies AB (“Atlas Antibodies”) today announce a strategic partnership aimed at accelerating innovation in tissue analysis and strengthening their respective positions in a growing global market. By combining Lumito’s proprietary high-sensitivity imaging technology with Atlas Antibodies’ extensively validated antibody portfolio, the collaboration is designed to create differentiated, value-driven solutions for research, translational applications, and quantitative analysis in tissue samples
”We are excited to partner with Atlas Antibodies, a company renowned for its scientific rigor and antibody validation standards. By combining our high-resolution imaging technology with Atlas Antibodies’ trusted antibody portfolio, we aim to unlock new possibilities in digital pathology and biomarker research”, says Sanna Wallenborg, CEO of Lumito.”Our collaboration with Lumito represents an important step toward enabling next-generation tissue analysis. Together, we can provide researchers with powerful tools that enhance accuracy, reproducibility, and insight in biomarker detection”, says Ingela Hofverberg, CEO of Atlas Antibodies.
About Atlas Antibodies
Atlas Antibodies is a Swedish life science company providing highly validated primary antibodies to researchers worldwide. Built on the Human Protein Atlas project, the company focuses on quality, reproducibility, and comprehensive validation to support reliable scientific discoveries.
For further information, please contact:
Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68
About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/
The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.
Ämnen i artikeln
Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging
18 februari, 09:20
Lumito AB (publ) (“Lumito” or the “Company”) and Atlas Antibodies AB (“Atlas Antibodies”) today announce a strategic partnership aimed at accelerating innovation in tissue analysis and strengthening their respective positions in a growing global market. By combining Lumito’s proprietary high-sensitivity imaging technology with Atlas Antibodies’ extensively validated antibody portfolio, the collaboration is designed to create differentiated, value-driven solutions for research, translational applications, and quantitative analysis in tissue samples
”We are excited to partner with Atlas Antibodies, a company renowned for its scientific rigor and antibody validation standards. By combining our high-resolution imaging technology with Atlas Antibodies’ trusted antibody portfolio, we aim to unlock new possibilities in digital pathology and biomarker research”, says Sanna Wallenborg, CEO of Lumito.”Our collaboration with Lumito represents an important step toward enabling next-generation tissue analysis. Together, we can provide researchers with powerful tools that enhance accuracy, reproducibility, and insight in biomarker detection”, says Ingela Hofverberg, CEO of Atlas Antibodies.
About Atlas Antibodies
Atlas Antibodies is a Swedish life science company providing highly validated primary antibodies to researchers worldwide. Built on the Human Protein Atlas project, the company focuses on quality, reproducibility, and comprehensive validation to support reliable scientific discoveries.
For further information, please contact:
Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68
About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/
The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.
Ämnen i artikeln
Aktieanalys
Saab
Rapporter i urval
Mildef
Rapporter i urval
Aktieanalys
Saab
Rapporter i urval
Mildef
Rapporter i urval
Marknadsöversikt
1 DAG %
Senast
1 mån
